Note 9 - License Agreements (Details Textual) - USD ($)		1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 28, 2023	Dec. 31, 2012	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Sep. 30, 2014	Jan. 31, 2012
Deferred Revenue, Current			$ 6,903,000		$ 6,903,000		$ 152,000
L F B License Agreement [Member]
License And Collaboration Agreement, Expenses Incurred					31,000,000
Royalty Expense			2,400,000		4,800,000
Accrued Royalties			2,400,000		2,400,000
L F B License Agreement [Member] | License Agreement Terms [Member]
Finite-Lived Intangible Asset, Useful Life (Year)									15 years
L F B License Agreement [Member] | Maximum [Member]
Additional Amount Receivable on Achievement of Pre-specified Milestones									$ 12,000,000
Sublicense Agreement With Ildong Pharmaceutical Co [Member]
Additional Amount Receivable on Achievement of Pre-specified Milestones		$ 5,000,000
Upfront Fee Received From Sub License		2,000,000
Income Tax Expense (Benefit)		$ 300,000
License Revenue			38,000	$ 38,000	114,000	$ 114,000
Deferred Revenue			300,000		300,000		500,000
Deferred Revenue, Current			200,000		200,000		200,000
Sublicense Agreement With Ildong Pharmaceutical Co [Member] | License Agreement Terms [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		15 years
Commercialization Agreement With Neuraxpharm [Member]
Additional Amount Receivable on Achievement of Pre-specified Milestones	$ 492,500,000
License and Collaboration Agreements, One-time, Non-refundable Payment	140,000,000		140,000,000
Additional Payments Upon Key Market Commercial Launch	$ 12,500,000
Royalty Percentage on Net Product Sales	30.00%
Agreement Buyback Period (Year)	2 years
The Umbralisib License [Member]
License And Collaboration Agreement, Expenses Incurred					24,000,000
Royalty Expense							200,000
Accrued Royalties			$ 0		$ 0		$ 3,000
Additional Amount Payable on Achievement of Pre-specified Milestones								$ 175,000,000